Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

J Transl Med. 2013 Apr 11:11:97. doi: 10.1186/1479-5876-11-97.


Background: Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multiple peptides is limited.

Methods: We conducted phase I trials using a mixture of multiple therapeutic peptide vaccines to evaluate their safety, immunogenicity and clinical response in patients with advanced/recurrent NSCLC. We administered two different combinations of four HLA-A24-restricted peptides. Two were peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2), and the third was a peptide derived from up-regulated lung cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]). The fourth peptide used was derived from TTK protein kinase (TTK) or cell division associated 1 (CDCA1). Vaccines were administered weekly by subcutaneous injection into the axillary region of patients with montanide ISA-51 incomplete Freund's adjuvant, until the disease was judged to have progressed or patients requested to be withdrawn from the trial. Immunological responses were primarily evaluated using an IFN-gamma ELiSPOT assay.

Results: Vaccinations were well tolerated with no severe treatment-associated adverse events except for the reactions that occurred at the injection sites. Peptide-specific T cell responses against at least one peptide were observed in 13 of the 15 patients enrolled. Although no patient exhibited complete or partial responses, seven patients (47%) had stable disease for at least 2 months. The median overall survival time was 398 days, and the 1- and 2-year survival rates were 58.3% and 32.8%, respectively.

Conclusion: Peptide vaccine therapy using a mixture of four novel peptides was found to be safe, and is expected to induce strong specific T cell responses.

Trial registration: These studies were registered with NCT00633724 and NCT00874588.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology*
  • Feasibility Studies
  • Female
  • Humans
  • Immunity
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / immunology*
  • Male
  • Middle Aged
  • Monitoring, Immunologic
  • Survival Analysis
  • Treatment Outcome
  • Vaccines, Subunit / immunology*
  • Vaccines, Subunit / therapeutic use*


  • Angiogenesis Inhibitors
  • Antigens, Neoplasm
  • Vaccines, Subunit

Associated data